Clinical Trial Update: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sofobuvir/velpatasvir fixed-dose combination over 12 weeks for chronic hepatitis C shows efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Sofosbuvir/Velpatasvir Fixed Dose Combination (sofosbuvir/velpatasvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2019-01-08